These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22748872)

  • 1. Influence of opioid consumption on serum prostate-specific antigen levels in men without clinical evidence of prostate cancer.
    Hosseini SY; Amini E; Safarinejad MR; Soleimani M; Lashay A; Farokhpey AH
    Urology; 2012 Jul; 80(1):169-73. PubMed ID: 22748872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opium consumption is negatively associated with serum prostate-specific antigen (PSA), free PSA, and percentage of free PSA levels.
    Safarinejad MR; Asgari SA; Farshi A; Iravani S; Khoshdel A; Shekarchi B
    J Addict Med; 2013; 7(1):58-65. PubMed ID: 23296201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
    Ochiai A; Fritsche HA; Babaian RJ
    Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
    Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
    Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
    BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
    Ornstein DK; Smith DS; Humphrey PA; Catalona WJ
    J Urol; 1998 Apr; 159(4):1234-7. PubMed ID: 9507843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
    Ornstein DK; Rao GS; Smith DS; Ratliff TL; Basler JW; Catalona WJ
    J Urol; 1997 Jan; 157(1):195-8. PubMed ID: 8976249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy.
    Tubaro A; De Nunzio C; Mariani S; Trucchi A; Miano R; Vicentini C; Miano L
    Urology; 2010 Aug; 76(2):436-41. PubMed ID: 20538320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.